E
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Erming Tian's research focuses on multiple myeloma, a hematologic malignancy. His work investigates prognostic factors and treatment outcomes for patients with this disease. Recent publications examine the clinical implications of minimal residual disease negativity and persistence, the association of specific chromosomal abnormalities with patient outcomes, and the role of genetic mutations such as BRAF and DIS3 in disease progression.
Dr. Tian also studies bone remineralization in multiple myeloma lytic lesions, suggesting a focus on the skeletal complications of the disease. His research has explored phenotypic markers in monoclonal gammopathy of unknown significance, indicating an interest in early detection and disease progression monitoring. He has a h-index of 31 with over 5,300 citations across more than 100 publications, and he leads a research group at the University of Arkansas for Medical Sciences, collaborating with colleagues including Shmuel Yaccoby, Michele Cottler‐Fox, Clyde Bailey, and Susan Panozzo.
Metrics
- h-index: 31
- Publications: 102
- Citations: 5,390
Selected Publications
-
Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma (2023)
-
Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma (2021)
-
Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma (2021)
-
Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience (2021)
Collaboration Network
Top Collaborators
Frits van Rhee
University of Arkansas for Medical Sciences
16 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Showing 5 of 16 shared publications
Maurizio Zangari
University of Arkansas for Medical Sciences
16 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Showing 5 of 16 shared publications
Jeffrey R. Sawyer
12 shared publications
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Showing 5 of 12 shared publications
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
10 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Showing 5 of 10 shared publications
Carolina Schinke
Winthrop Rockefeller Foundation
10 shared publications
In database
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Showing 5 of 10 shared publications
Antje Hoering
10 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 10 shared publications
Bart Barlogie
10 shared publications
In database
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Data from <i>BRAF</i> and <i>DIS3</i> Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 10 shared publications
Meera Mohan
Medical College of Wisconsin (US)
6 shared publications
- Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma
- Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma
- Bone remineralization of lytic lesions in multiple myeloma – The Arkansas experience
- Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Showing 5 of 6 shared publications
Yogesh Jethava
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Alan Mitchell
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Joshua Epstein
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Shmuel Yaccoby
6 shared publications
In database
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Sarah Waheed
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Rashid Khan
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Xenofon Papanikolaou
6 shared publications
- Supplementary Tables from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Data from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
- Supplementary Figures from Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Showing 5 of 6 shared publications
Similar Researchers
Based on overlapping research topics
Manojna Konda
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Genomics and Diagnostics
Health Disparities and Outcomes
Sanjay Muttineni
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Genomics and Diagnostics
Cancer Treatment and Pharmacology
Shoon Oo
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Genomics and Diagnostics
Cancer Treatment and Pharmacology
Jaskirat S Sethi
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Health Disparities and Outcomes
Cancer Treatment and Pharmacology
Frits Vanrhee
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Health Disparities and Outcomes
Cancer Treatment and Pharmacology
Kristin Kampevold Larsen
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Health Disparities and Outcomes
Cancer Treatment and Pharmacology